Invention Grant
- Patent Title: 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
-
Application No.: US16428386Application Date: 2019-05-31
-
Publication No.: US11241446B2Publication Date: 2022-02-08
- Inventor: Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
- Applicant: Sage Therapeutics, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Sage Therapeutics, Inc.
- Current Assignee: Sage Therapeutics, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Honigman LLP
- Agent Kathryn D. Doyle; Jonathan P. O'Brien
- Priority: WOPCT/CN2013/074323 20130417
- Main IPC: A61K31/58
- IPC: A61K31/58 ; A61K31/473 ; C07J3/00 ; C07J7/00 ; C07J15/00 ; C07J43/00 ; A61K9/00 ; C07J5/00 ; A61K31/573 ; C07J1/00 ; C07J13/00 ; C07J21/00 ; C07J31/00

Abstract:
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
Public/Granted literature
- US20200155576A1 19-NOR C3, 3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF Public/Granted day:2020-05-21
Information query